Endocrinology

Alexis Marcotte-Chénard, PhD, discusses his presentation on “exercise snacks” and how they can lower blood pressure and improve HbA1c in sedentary patients.

Sood discusses emerging diabetes technologies, from automated insulin delivery to dual glucose-ketone monitoring, at ADA 2026.

Teplizumab, which has recently seen a substantial label expansion into pediatric patients, is matching its safety and efficacy data in the clinic.

Catch up on major trial results, key FDA decisions, and more.

View the top 6 trials to watch ahead of a star-studded ADA 2026.

Jamie Wood, MD, discusses the impact of Afrezza’s recent FDA approval for pediatric patients with type 1 and type 2 diabetes.

Stay updated with the latest healthcare breakthroughs, including FDA approvals and phase 3 data.

Diabetes Dialogue cohosts Diana Isaacs, PharmD, and Natalie Bellini, DNP, cover topline data from the TRIUMPH-1 trial of retatrutide for obesity management.

The FDA has approved fast-acting inhaled insulin Afrezza for pediatric patients aged 6-18 years with T1D or T2D.

This episode covers the FDA’s recent approval of MannKind’s inhaled insulin Afrezza for patients aged 6-18 years with either T1D or T2D.

Diabetes Dialogue cohosts Diana Isaacs, PharmD, and Natalie Bellini, DNP, cover the recent approval of the Libre Duo and Libre Duo 10 Day monitors.

This episode covers Abbott’s Libre Duo and Libre Duo 10 Day systems, Eli Lilly’s retatrutide, and the recent Dexcom sensor theft.

The FDA accepted Bayer’s sNDA for finerenone in adults with type 1 diabetes and CKD based on albuminuria data from FINE-ONE.

Retatrutide successfully reduced body weight versus placebo in adults with obesity or overweight in topline phase 3 TRIUMPH-1 results.

Diabetes Dialogue cohosts Diana Isaacs, PharmD, and Natalie Bellini, DNP, cover more of the upcoming news releases announced for ADA 2026.

Diabetes Dialogue cohosts Diana Isaacs, PharmD, and Natalie Bellini, DNP, discuss the presentations that they’re looking forward to at ADA 2026.

Carel le Roux, PhD, MSC, discusses the investigative dual GLP-1/glucagon agonist’s weight loss efficacy in patients with obesity and overweight without T2D.

This episode covers key trial results and presentations to keep an eye on as ADA 2026 approaches.

Fechner discusses the 2-year data from an open-label extension of the CAHtalyst Pediatric study, maintaining substantial glucocorticoid dose lowering.

Stay updated with the latest healthcare breakthroughs, including FDA submissions and new cardiology guidelines.

Schatz highlights the current limitations to a broader integration of T1D screening and suggests methods to circumvent these blockages.

The FDA has cleared the EndoTool IV Cloud for hospital IV insulin dosing support, expanding Glooko’s inpatient platform via the 510(k) pathway.

The NDA submission follows positive results from the CALIBRATE phase 3 trial, which evaluated encaleret versus standard-of-care in adults with ADH1.

This episode covers recent advancements in treating type 1 diabetes, including the Tandem AID system for pregnant women and teplizumab for adolescents.

The new recommendations outline glucocorticoid tapering strategies for adults and children with classic CAH after starting crinecerfont.